PSA redemption.

Forget a genomic risk score, predictive scrutiny of PSA is making a comeback. This secondary analysis of the massive prospective PLCO study demonstrates an association between baseline PSA levels at age 55-60 years and long term risk of developing clinically-significant prostate cancer. | Kovac, JAMA Netw Open 2020